X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.611
+0.004 (0.66%)
At close: Dec 20, 2024, 4:00 PM
0.640
+0.029 (4.69%)
After-hours: Dec 20, 2024, 4:50 PM EST
X4 Pharmaceuticals Revenue
X4 Pharmaceuticals had revenue of $560.00K in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $1.12M.
Revenue (ttm)
$1.12M
Revenue Growth
n/a
P/S Ratio
108.93
Revenue / Employee
$12,075
Employees
93
Market Cap
104.26M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PetMed Express | 259.34M |
Quipt Home Medical | 245.92M |
MDxHealth | 84.71M |
Champions Oncology | 53.57M |
Assembly Biosciences | 28.33M |
Tonix Pharmaceuticals Holding | 11.29M |
XFOR News
- 18 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference - GlobeNewsWire
- 5 weeks ago - X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024 - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences - GlobeNewsWire